Chemerin, vaspin and insulin resistance in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 17, Issue 9, 2010, Pages 661-667

  Kukla, Michał ^a   Zwirska Korczala, K ^a   Gabriel, A ^a   Waluga, M ^a   Warakomska, I ^a   Szczygiel, B ^a   Berdowska, A ^b   Mazur, W ^a   Wozniak Grygiel, E ^a   Kryczka, W ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

^c JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

chemerin; chronic hepatitis C; insulin resistance; liver; vaspin

Indexed keywords

ADIPOCYTOKINE; CHEMERIN; LEPTIN; LIPID; UNCLASSIFIED DRUG; VASPIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBROSIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UPREGULATION;

ADIPOKINES; ADULT; CHEMOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SERPINS;

EID: 77955395340     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01224.x     Document Type: Article

References (33)

1. Fartoux L, Poujol-Robert A, Guechot J et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 1008. (Pubitemid 40873917)
2. Yoneda M, Saito S, Ikeda T et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007 14 (9 600 607.
3. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis - pathogenic mechanism and clinical implications. Aliment Pharmacol Ther 2005 22 (Suppl. 2 52 55.
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000 133 : 592 599.
5. Perlemuter G, Sabile A, Letteron P, Strathdee SA, Szklo M, Thomas DL Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002 16 : 185 195.
6. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 1364.
7. Castaneda-Sceppa C, Bermudez OI, Wanke C, Forrester JE. Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2008 15 (12 878 887.
8. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C infection and fibrosis progression. Gastroenterology 2003 125 : 1695 1704.
9. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006 13 : 73 80.
10. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004 41 : 132 138.
11. Camma C, Bruno S, Di Marco V et al. Insulin resistance is associated with steatosis in nindiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006 43 : 64 71.
12. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008 12 : 741 751.
13. Zwirska-Korczala K, Kukla M, Ziolkowski A et al. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp Clin Hep 2005 1 (2 OR60 OR65.
14. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008 15 : 91 101.
15. Bozaoglu K, Bolton K, McMillan J et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007 148 (10 4687 4694.
16. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population - a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008 152 (2 217 221.
17. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008 15 (2 226 233.
18. Yoshimura T, Oppenheim JJ. Chemerin reveals a chimeric nature. J Environ Monit 2008 205 (10 2187 2190.
19. Cash JL, Hart R, Russ A et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Environ Monit 2008 205 (4 767 775.
20. Klöting N, Berndt J, Kralisch S et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006 339 : 430 436.
21. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008 17 (3 327 333.
22. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995 22 : 112 114.
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Teri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 94 : 2467 2474.
24. Cua IHY, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007 46 : 66 73.
25. Petit JM, Bour JB, Galland-Jos C et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001 35 : 279 283.
26. Kukla M, Warakomska I, Gabriel A et al. Serum levels of sICAM-1, TNFα, sTNF-R1, and sTNF-R2 in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Exp Clin Hep 2008 4 (1 OR12 OR20.
27. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008 48 (1 80 87.
28. Wolf D, Hallmann R, Sass G et al. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR-1-relevance for concanavalin A-induced hepatitis. J Immunol 2001 166 (2 1300 1307.
29. Kukla M, Zwirska-Korczala K, Gabriel A et al. sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Ther Adv Gastroenterol 2009 2 : 79 90.
30. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T, LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003 39 : 1049 1055.
31. Takahasi M, Takahashi Y, Takahashi K et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008 582 : 573 578.
32. Youn BS, Klöting N, Kratzsch J et al. Serum vaspin concentration in human obesity and type 2 diabetes. Diabetes 2008 57 : 372 377.
33. Seeger J, Ziegelmeier M, Bachmann A et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008 93 : 247 251.